Loading...

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

BACKGROUND: Recombinant activated factor VII (rFVIIa, NovoSeven(®)) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX. OBJECTIVE: To review the evidence supporting the use of rFVIIa for the treatment of patients with congenital blee...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Johansson, Pär I, Ostrowski, Sisse R
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2010
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2915535/
https://ncbi.nlm.nih.gov/pubmed/20689697
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!